The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials

S. M. Arabi; M. Shahraki-Jazinaki; M. Chambari; L. S. Bahrami; S. Sabeti; M. I. M. Gubari; Basil D. Roufogalis; A. Sahebkar

doi:10.1186/s40360-024-00740-y

The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials

S. M. Arabi, M. Shahraki-Jazinaki, M. Chambari, L. S. Bahrami, S. Sabeti, M. I. M. Gubari, Basil D. Roufogalis, A. Sahebkar

Western Sydney University

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background: Previous studies investigating the effect of oral supplementation of paricalcitol on reactive protein levels in chronic kidney disease (CKD) patients reported inconsistent findings. In this systematic review and meta-analysis, we have analyzed and interpreted the results obtained from previous randomized clinical trials on the effect of paricalcitol on C-reactive protein in CKD patients in the literature. Methods: MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases were searched until January 2023 and related articles were obtained through a careful screening process allowing extraction of required data from selected articles. The effect size was calculated using a random effect model and weighted mean differences (WMD) and 95% confidence intervals (CI). Heterogeneity among studies was evaluated using Cochran's Q test and I2. Results: Amongst the 182 articles obtained from the initial search, 4 studies (6 arms) were finally included in the meta-analysis. Pooled analysis shows that C-reactive protein levels significantly decrease after oral supplementation with paricalcitol (WMD: -2.55 mg/L, 95% CI (-4.99 to -0.11; P = 0.04). The studies used in this meta-analysis showed significant heterogeneity (I2 = 66.3% and P = 0.01). Conclusion: Oral paricalcitol supplementation in CKD patients can significantly reduce C-reactive protein levels, which may prevent CKD progression.

Original language	English
Article number	19
Number of pages	9
Journal	BMC Pharmacology and Toxicology
Volume	25
Issue number	1
DOIs	https://doi.org/10.1186/s40360-024-00740-y
Publication status	Published - Dec 2024

Open Access - Access Right Statement

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data

Notes

WIP in RD

Keywords

C-reactive protein
Chronic kidney disease
Meta-analysis
Paricalcitol
Systematic review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40360-024-00740-y

Fingerprint

Dive into the research topics of 'The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials'. Together they form a unique fingerprint.

Cite this

Arabi, S. M., Shahraki-Jazinaki, M., Chambari, M., Bahrami, L. S., Sabeti, S., Gubari, M. I. M., Roufogalis, B. D., & Sahebkar, A. (2024). The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials. BMC Pharmacology and Toxicology, 25(1), Article 19. https://doi.org/10.1186/s40360-024-00740-y

@article{33681544ab764d2691b3c0c05bf3475a,

title = "The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials",

abstract = "Background: Previous studies investigating the effect of oral supplementation of paricalcitol on reactive protein levels in chronic kidney disease (CKD) patients reported inconsistent findings. In this systematic review and meta-analysis, we have analyzed and interpreted the results obtained from previous randomized clinical trials on the effect of paricalcitol on C-reactive protein in CKD patients in the literature. Methods: MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases were searched until January 2023 and related articles were obtained through a careful screening process allowing extraction of required data from selected articles. The effect size was calculated using a random effect model and weighted mean differences (WMD) and 95% confidence intervals (CI). Heterogeneity among studies was evaluated using Cochran's Q test and I2. Results: Amongst the 182 articles obtained from the initial search, 4 studies (6 arms) were finally included in the meta-analysis. Pooled analysis shows that C-reactive protein levels significantly decrease after oral supplementation with paricalcitol (WMD: -2.55 mg/L, 95% CI (-4.99 to -0.11; P = 0.04). The studies used in this meta-analysis showed significant heterogeneity (I2 = 66.3% and P = 0.01). Conclusion: Oral paricalcitol supplementation in CKD patients can significantly reduce C-reactive protein levels, which may prevent CKD progression.",

keywords = "C-reactive protein, Chronic kidney disease, Meta-analysis, Paricalcitol, Systematic review",

author = "Arabi, {S. M.} and M. Shahraki-Jazinaki and M. Chambari and Bahrami, {L. S.} and S. Sabeti and Gubari, {M. I. M.} and Roufogalis, {Basil D.} and A. Sahebkar",

year = "2024",

month = dec,

doi = "10.1186/s40360-024-00740-y",

language = "English",

volume = "25",

journal = "BMC Pharmacology and Toxicology",

issn = "2050-6511",

publisher = "BioMed Central",

number = "1",

}

Arabi, SM, Shahraki-Jazinaki, M, Chambari, M, Bahrami, LS, Sabeti, S, Gubari, MIM, Roufogalis, BD & Sahebkar, A 2024, 'The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials', BMC Pharmacology and Toxicology, vol. 25, no. 1, 19. https://doi.org/10.1186/s40360-024-00740-y

The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials. / Arabi, S. M.; Shahraki-Jazinaki, M.; Chambari, M. et al.
In: BMC Pharmacology and Toxicology, Vol. 25, No. 1, 19, 12.2024.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials

AU - Arabi, S. M.

AU - Shahraki-Jazinaki, M.

AU - Chambari, M.

AU - Bahrami, L. S.

AU - Sabeti, S.

AU - Gubari, M. I. M.

AU - Roufogalis, Basil D.

AU - Sahebkar, A.

PY - 2024/12

Y1 - 2024/12

N2 - Background: Previous studies investigating the effect of oral supplementation of paricalcitol on reactive protein levels in chronic kidney disease (CKD) patients reported inconsistent findings. In this systematic review and meta-analysis, we have analyzed and interpreted the results obtained from previous randomized clinical trials on the effect of paricalcitol on C-reactive protein in CKD patients in the literature. Methods: MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases were searched until January 2023 and related articles were obtained through a careful screening process allowing extraction of required data from selected articles. The effect size was calculated using a random effect model and weighted mean differences (WMD) and 95% confidence intervals (CI). Heterogeneity among studies was evaluated using Cochran's Q test and I2. Results: Amongst the 182 articles obtained from the initial search, 4 studies (6 arms) were finally included in the meta-analysis. Pooled analysis shows that C-reactive protein levels significantly decrease after oral supplementation with paricalcitol (WMD: -2.55 mg/L, 95% CI (-4.99 to -0.11; P = 0.04). The studies used in this meta-analysis showed significant heterogeneity (I2 = 66.3% and P = 0.01). Conclusion: Oral paricalcitol supplementation in CKD patients can significantly reduce C-reactive protein levels, which may prevent CKD progression.

AB - Background: Previous studies investigating the effect of oral supplementation of paricalcitol on reactive protein levels in chronic kidney disease (CKD) patients reported inconsistent findings. In this systematic review and meta-analysis, we have analyzed and interpreted the results obtained from previous randomized clinical trials on the effect of paricalcitol on C-reactive protein in CKD patients in the literature. Methods: MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases were searched until January 2023 and related articles were obtained through a careful screening process allowing extraction of required data from selected articles. The effect size was calculated using a random effect model and weighted mean differences (WMD) and 95% confidence intervals (CI). Heterogeneity among studies was evaluated using Cochran's Q test and I2. Results: Amongst the 182 articles obtained from the initial search, 4 studies (6 arms) were finally included in the meta-analysis. Pooled analysis shows that C-reactive protein levels significantly decrease after oral supplementation with paricalcitol (WMD: -2.55 mg/L, 95% CI (-4.99 to -0.11; P = 0.04). The studies used in this meta-analysis showed significant heterogeneity (I2 = 66.3% and P = 0.01). Conclusion: Oral paricalcitol supplementation in CKD patients can significantly reduce C-reactive protein levels, which may prevent CKD progression.

KW - C-reactive protein

KW - Chronic kidney disease

KW - Meta-analysis

KW - Paricalcitol

KW - Systematic review

UR - https://hdl.handle.net/1959.7/uws:76338

UR - http://www.scopus.com/inward/record.url?scp=85185900901&partnerID=8YFLogxK

U2 - 10.1186/s40360-024-00740-y

DO - 10.1186/s40360-024-00740-y

M3 - Article

SN - 2050-6511

VL - 25

JO - BMC Pharmacology and Toxicology

JF - BMC Pharmacology and Toxicology

IS - 1

M1 - 19

ER -

Arabi SM, Shahraki-Jazinaki M, Chambari M, Bahrami LS, Sabeti S, Gubari MIM et al. The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials. BMC Pharmacology and Toxicology. 2024 Dec;25(1):19. doi: 10.1186/s40360-024-00740-y

The effect of oral supplementation of paricalcitol on C-reactive protein levels in chronic kidney disease patients : GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials

Abstract

Open Access - Access Right Statement

Notes

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this